The recent series A financing by Bambusa Therapeutics Inc. to fund bispecific antibodies for immunological and inflammatory disorders proved investor faith in the new approach with a proven mechanism.

Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting bispecific antibodies for immunological and inflammatory disorders.